LGND
Ligand Pharmaceuticals Incorporated
NASDAQ: LGND · HEALTHCARE · BIOTECHNOLOGY
$220.48
+0.46% today
Updated 2026-06-05
Market cap
$5.12B
P/E ratio
33.27
P/S ratio
18.66x
EPS (TTM)
$7.68
Dividend yield
—
52W range
$110 – $259
Volume
0.2M
WallStSmart proprietary scores
67
out of 100
Grade: B
Buy
Investment rating
8.0
Growth
A8.0
Quality
A8.5
Profitability
A3.3
Valuation
D4/9
Piotroski F-Score
Moderate
2.8
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →199 stocks currently score above 75
Price targets
Analyst target
$271.80
+23.28%
12-Month target
$185.80
-15.73%
Intrinsic (DCF)
$160.49
Margin of safety
-15.87%
2 Strong Buy7 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Profit margin 55.90% — above average
+ Free cash flow $48.46M — positive
+ Revenue growth 14.10% QoQ
+ Debt/equity 0.45x — low leverage
Risks
- 15.87% above intrinsic value
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM | 2026 (E) |
|---|---|---|---|---|---|---|
| Revenue | $196.25M | $131.31M | $167.13M | $268.09M | $274.48M | $0.3B |
| Net income | $-33.36M | $52.15M | $-4.03M | $124.45M | $-13.35M | — |
| EPS | — | — | — | — | $7.68 | $9.00 |
| Free cash flow | $119.93M | $-4.27M | $77.41M | $48.91M | $48.46M | — |
| Profit margin | -17.00% | 39.72% | -2.41% | 46.42% | 55.90% | — |
Peer comparison
Smart narrative
Ligand Pharmaceuticals Incorporated trades at $220.48. representing a P/E of 33.27x trailing earnings. Our Smart Value Score of 67/100 indicates the stock is good. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 2.79, it sits in the grey zone. TTM revenue stands at $274.48M. with profit margins at 55.90%. Our DCF model estimates intrinsic value at $160.49.
Frequently asked questions
What is Ligand Pharmaceuticals Incorporated's stock price?
Ligand Pharmaceuticals Incorporated (LGND) trades at $220.48, on a P/E of 33.3x and a P/S of 18.7x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Ligand Pharmaceuticals Incorporated overvalued?
Ligand Pharmaceuticals Incorporated carries a Smart Value Score of 67/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $160.49 against the $220.48 price, so on cash flow terms the market is paying a premium for Ligand Pharmaceuticals Incorporated's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Ligand Pharmaceuticals Incorporated (LGND)?
The 12-month analyst consensus target is $271.80, about 23.3% above the current $220.48. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the future stock price of LGND by 2030?
Our research-backed model puts the 2030 base case at $344.03, built from revenue projections, a growth-adjusted P/S multiple, net debt, and share dilution. It is a scenario rather than a prediction, and the bull and bear cases around it matter more than the single number when you are sizing a position.
What is the intrinsic value of Ligand Pharmaceuticals Incorporated (LGND)?
Our DCF model estimates intrinsic value at $160.49, a -15.9% margin of safety versus today's $220.48. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Ligand Pharmaceuticals Incorporated's revenue?
Ligand Pharmaceuticals Incorporated's trailing twelve-month revenue is $274.48M, and our model projects it reaching about $820.00M by 2030. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Ligand Pharmaceuticals Incorporated's Altman Z-Score is 2.79, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio18.66x
ROE15.40%
Beta1.04
50D MA$226.13
200D MA$199.39
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—